

Supplementary Table 1. Multivariate analyses for overall survival after brain metastasis and brain metastasis-specific survival after brain metastasis

Factor	OSBM		BMSS	
	Hazard ratio	<i>p</i> -value	Hazard ratio	<i>p</i> -value
Treatment		0.072		0.084
FBT	Reference		Reference	
Non-FBT	0.66 (0.42–1.04)		0.57 (0.31–1.08)	
ER		0.952		
Positive	Reference		NA	
Negative	0.96 (0.29–3.19)			
PR		0.001		0.002
Positive	Reference		Reference	
Negative	0.37 (0.20–0.70)		0.36 (0.19–0.69)	
Histologic grade				0.116
I, II	NA		Reference	
III			0.82 (0.34–1.12)	
Subtype		0.453		
TN	Reference		NA	
HR+HER2–	0.80 (0.19–3.28)	0.755		
HR+HER2+	1.11 (0.30–4.14)	0.878		
HR–HER2+	0.66 (0.35–1.27)	0.215		
No. of metastases in brain		0.02		0.028
Multiple (≥5)	Reference		Reference	
Single	0.43 (0.23–0.80)	0.008	0.40 (0.18–0.90)	0.026
Oligometastasis (2–4)	0.64 (0.40–1.02)	0.06	0.45 (0.23–0.90)	0.024

OSBM= overall survival after brain metastasis; BMSS= brain metastasis-specific survival; FBT = focal brain treatment; ER= estrogen receptor; NA= not associated; PR= progesterone receptor; TN= triple-negative; HR= hormone receptor; HER2= human epidermal growth factor receptor 2.